Research programme: phosphatidylinositol 3 kinase inhibitors - Infinity Pharmaceuticals

Drug Profile

Research programme: phosphatidylinositol 3 kinase inhibitors - Infinity Pharmaceuticals

Alternative Names: INK 055; IPI-1828; IPI-443; phosphatidylinositol 3 kinase inhibitors - Intellikine

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellikine
  • Developer Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Takeda America Holdings
  • Class Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Haematological malignancies; Inflammation; Solid tumours

Most Recent Events

  • 31 Mar 2017 Infinity Pharmaceuticals has patents pending for compositions of matter, pharmaceutical compositions, methods of use and synthetic methods for PI3K-gamma programme in World
  • 28 Sep 2016 Phosphatidylinositol 3 kinase inhibitors are still in preclinical development for Haematological malignancies, Solid tumours, Autoimmune disorders and Inflammation in USA (Infinity Pharmaceuticals pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top